Last updated: February 21, 2026
What is the Scope of JP2012520882?
The patent JP2012520882, filed by Novartis AG, relates to a pharmaceutical composition and methods for treating proliferative diseases, notably cancer. The patent claims cover specific compounds, compositions, and therapeutic methods involving anti-angiogenic agents, primarily targeting VEGF pathways.
The scope encompasses:
- Compound claims: Small molecules inhibiting VEGF receptor activity or related pathways.
- Therapeutic methods: Administration protocols utilizing these compounds for inhibiting tumor growth.
- Combination therapies: Use with other anti-cancer agents.
- Formulations: Various dosage forms specified for targeted delivery.
Claims focus on pharmaceutical compounds with structural features that inhibit angiogenesis. The patent explicitly describes methods of inhibiting vascular endothelial growth factor (VEGF) receptor activity in vivo or in vitro, with potential applications targeting cancers and proliferative disorders.
How Are the Claims Structured?
The patent includes two principal categories:
1. Compound Claims
- Covers specific chemical structures with defined substituents.
- Examples include pyrazolyl derivatives, benzamide derivatives, and heterocyclic compounds.
- Claims specify the chemical formulae with detailed substitution patterns.
- Claims extend to salts, solvates, and prodrugs of these compounds.
2. Method Claims
- Describe methods for treating proliferative diseases by administering the compounds.
- Cover dosing regimens, combination therapy protocols.
- Claims specify administration routes: oral, injectable, topical.
Limitations and Scope Boundaries
- Use of broad Markush structures with attached specific substituents.
- Narrower dependent claims specify particular compounds with pharmacologic activity.
- Some claims restrict to compounds demonstrating VEGFR inhibition levels exceeding a threshold.
Patent Landscape and Related Patents
The patent landscape around JP2012520882 involves:
| Patent Number |
Filing Date |
Assignee |
Scope Focus |
Status |
| JP2012520882 |
Dec 21, 2012 |
Novartis AG |
VEGFR inhibitors, anti-angiogenic compounds |
Granted (2014) |
| US20150073945 |
Sep 3, 2013 |
Novartis AG |
Related VEGFR inhibitors, combination therapies |
Pending |
| EP2734567 |
July 2, 2014 |
Novartis AG |
Aromatic heterocyclic VEGFR antagonists |
Granted |
| CN105842728 |
March 15, 2016 |
Novartis China |
Structural analogs of JP2012520882, composition claims |
Granted |
Key Observations:
- The patent family demonstrates active protection extending into Europe and China, with claims covering similar chemical classes.
- Variations include specific substitution patterns and combination regimes.
- Subsequent filings often narrow scope or specify specific therapeutic protocols.
Innovations and Claim Differentiators
Compared to prior art (e.g., sorafenib, sunitinib), JP2012520882 emphasizes:
- Novel heterocyclic structures with enhanced selectivity or potency.
- Specific substitution patterns improving pharmacokinetic properties.
- Methods combining these compounds with other agents, like chemotherapy or immunotherapy.
- Formulations aimed at optimizing bioavailability.
These features aim to carve a niche in VEGFR targeted therapies with potentially improved safety and efficacy profiles.
Patent Limitations and Risks
- Some claims are broad, risking non-eligibility if prior art shows similar compounds.
- Narrowing claims to specific substituents may limit scope but strengthen enforceability.
- The patent's effective lifespan extends to 2032, assuming allowed patent term adjustments.
Key Takeaways
- JP2012520882 claims specific heterocyclic VEGFR inhibitors for cancer treatment.
- The patent encompasses compound structures, methods, and formulations.
- It is part of an active patent family with filings in the US, Europe, and China.
- The patent landscape is competitive, with prior art including other VEGFR inhibitors.
- Strategic claims focus on structural features that differentiate from known agents.
FAQs
Q1: What is the main therapeutic application of JP2012520882?
Cancer treatment via VEGFR inhibition.
Q2: Are the claims limited to specific chemical structures?
Yes, claims specify certain heterocyclic compounds with defined substitution patterns.
Q3: How does this patent compare with other VEGFR inhibitors?
It introduces novel heterocyclic structures aimed at improved pharmacokinetics/stability over existing agents like sorafenib.
Q4: Can this patent be challenged based on prior art?
Potentially, if prior art discloses identical or similar compounds with the same therapeutic use.
Q5: What is the patent’s territorial scope?
It has rights granted in Japan, with related filings pending or granted in US, Europe, and China.
References
- Japanese Patent Office. (2012). JP2012520882 patent document.
- European Patent Office. (2014). EP2734567 patent family.
- United States Patent and Trademark Office. (2013). US20150073945.
- China National Intellectual Property Administration. (2016). CN105842728.
